Entegris Inc vs Mesoblast Limited — how do they compare? Entegris Inc trades at $157.96 (market cap $22.95B), while Mesoblast Limited trades at $16.98 (market cap $2.21B). The key difference: Entegris Inc is far larger — about 10.4× Mesoblast Limited's market cap, and Entegris Inc pays a 0.27% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| ENTG | MESO | |
|---|---|---|
Market Cap | $22.95B | $2.21B |
Sector | Technology | Technology |
52-Week High | $184.00 | $20.96 |
52-Week Low | $68.80 | $12.88 |
Enterprise Value | $26.16B | $2.21B |
Dividend Yield | 0.27% | — |
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $144.21, down 5.17% over 24 hours, with a bullish technical outlook from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with $0.93 EPS, driven by AI-related semiconductor demand. Financials show a net income margin of 9.18% and positive operating cash flow of $695.40M in 2025, though valuation ratios like a P/E of 75.11 appear elevated.
Outlook remains positive due to robust earnings growth and AI tailwinds, but high valuation and competitive pressures pose risks. Analyst consensus is bullish with a $188.67 price target, suggesting 31% upside, supported by institutional buying interest and strong media sentiment from recent news highlights.
No Aura AI signal available yet.
Trailing returns across standard periods
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →